Prolonged Disease Stabilization and Tolerability in a Nuclear Protein in Testis Midline Carcinoma Patient Treated with Dual Histone Deacetylase and Phosphoinositide 3-Kinase Inhibitor CUDC-907

Münster, Pamela N.; Wu, Nilson; McMahon, Meaghan; Gharavi, Robert; Tuck, David

doi:10.4236/crcm.2018.77039

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, multimodality protocols including aggressive complete surgical resection followed by postoperative radiotherapy and/or chemoradiotherapy are usually advocated. Clinical trials of bromodomain and extraterminal motif (BET) inhibitors [ 20 ] and histone deacetylase inhibitors (HDACis) [ 21 ] are currently underway, and preliminary results are promising.…”

Section: Discussionmentioning

confidence: 99%

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Crocetta

Botti

Fornaciari

et al. 2021

Head and Neck Pathol

View full text Add to dashboard Cite

NUT carcinoma (NUT-C) is a relatively new malignancy that was recently listed in the 4th edition of the WHO Classification of Head and Neck Tumors in 2017. NUT carcinoma is a rare, aggressive, poorly differentiated carcinoma genetically defined by chromosomal rearrangement of the nuclear protein in testis (NUTM1) gene. The prognosis is extremely poor, with a mean survival < 1 year. Recent publications suggest a multimodality treatment approach. In the existing literature, only a few reports of sinonasal NUT-C have been reported. Sinonasal NUT-C is considered a very rare entity, but because of its recent inclusion as a head and neck malignancy, its true prevalence is unknown. We report the case of a 56-year-old woman with NUT-C of the sinonasal cavities. In the case reported, the coexistence of Coronavirus disease 2019 (COVID-19)-related nasal congestion delayed the diagnosis of NUT-C. Clinical presentation, diagnosis and treatment modalities are discussed together with a review of the literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Crocetta

Botti

Fornaciari

et al. 2021

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…In their study, Munster et al. [67] reported a case of NUT carcinoma patients treated with CUDC-907 after two previous treatments with a long-term stable disease of more than 32 months. The literature suggested that CUDC-907 was most effective against NUT carcinoma cells among MYC-targeted drugs (including BET and HDAC inhibitors), followed by panobinostat (an HDAC inhibitor) and AZD5153 (a divalent BET inhibitor) [65] .…”

Section: Therapy Strategiesmentioning

confidence: 99%

Nuclear protein in testis carcinoma of the lung

Chen

2023

Translational Oncology

View full text Add to dashboard Cite

“…HDAC inhibition potently suppresses MYC expression at the transcriptional level, while PI3K inhibition results in enhanced ubiquitin-mediated MYC protein degradation at the post-translational level. Munster et al reported a case of prolonged disease stabilization for over 32 months in an NMC patient treated with CUDC-907 after two prior treatments 55…”

Section: Therapeutic Management: From Orphan To Target Diseasementioning

confidence: 99%

<p>NUT midline carcinoma of the head and neck: current perspectives</p>

Napolitano¹,

Venturelli²,

Molinaro³

et al. 2019

OTT

View full text Add to dashboard Cite

: NUT midline carcinoma (NMC) is a rare and aggressive subtype of squamous carcinoma that typically arises from midline supradiaphragmatic structures, frequently from the head and neck area. NMC is genetically driven by a chromosomal rearrangement involving the NUT gene, which forms oncoproteins considered major pathogenic drivers of cellular transformation. Diagnosis of NMC has been made remarkably easier with the availability of a commercial antibody against NUT, and can be established through positive nuclear immunohistochemical staining. Although NMC remains an underrecognized malignancy, in recent years there has appeared to be increasing awareness of disease and frequency of diagnosis in adults. To date, a standard treatment for head and neck NMC has not been established and a multimodal approach with systemic chemotherapy, surgery and radiation therapy is currently adopted in clinical practice. Recently, BET inhibitors and histone deacetylase inhibitors have emerged as two promising classes of targeted agents, currently investigated in clinical trials for adults with head and neck NMC. At the same time, combination approaches and novel targeted agents, such as next-generation BET inhibitors and CDK9 inhibitors, have shown preclinical activity. The present review explores the clinical pathological characteristics of NMC of the head and neck and presents the current state of the art on diagnosis, prognosis, and treatment of this rare but lethal disease.

show abstract

Prolonged Disease Stabilization and Tolerability in a Nuclear Protein in Testis Midline Carcinoma Patient Treated with Dual Histone Deacetylase and Phosphoinositide 3-Kinase Inhibitor CUDC-907

Cited by 5 publications

References 32 publications

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Nuclear protein in testis carcinoma of the lung

<p>NUT midline carcinoma of the head and neck: current perspectives</p>

Contact Info

Product

Resources

About